Abstract: The present invention is directed to an isolated delta-6 desaturase gene from Schizochytrium. It is further directed to the cloning of delta-6 desaturase derived from Schizochytrium in Yeast. The nucleic acid sequence and the amino acid sequences of the delta-6 desaturase are disclosed. Further disclosed are the constructs, vector comprising the gene encoding the enzyme delta-6 desaturase in functional combination with the heterologous regulatory sequences. The novel delta-6 desaturase can be used in a metabolic pathway to convert linoleic acid to gamma linolenic acid (omega-6 pathway). The invention provides the identification, isolation of these novel nucleic acids from Schizochytrium that encode the above-mentioned proteins. The invention specifically exemplifies recombinant yeast cells harboring the vector comprising the delta-6 desaturase gene and by the virtue of the enzyme produced shall be able to produce gamnia-linolenic acid.

Abstract: The present invention relates to a recombinant method of production of activated Protein C. The invention relates to a method of construction, transformation, expression, purification and production of recombinant activated human protein C. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells.

Abstract: The present invention is directed to novel Octanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that are associated with the same. In addition, the present invention provides pharmaceutical compositions useful in inhibiting DPP-IV enzyme, comprising a therapeutically effective amount of Octanoic acid derivatives. Moreover, the present invention provides a method of inhibiting DPP-IV comprising administering to a mammal in need of such treatment a therapeutically effective amount of a single or a combination of Octanoic acid derivatives of the invention. The invention further relates to the kits and other articles of manufacture for treating disease states associated with DPP-IV enzyme.

Abstract: The present invention relates to the recombinant method used for the production of a highly glycosylated form (in total five N linked glycosylations as opposed to three N linked glyosylations in the natural EPO) of erythropoietin. The added sites for glycosylation will result in greater number of carbohydrate chains, and higher sialic acid content than human EPO, which in turn would impart to the recombinant molecule a longer half-life. The invention further relates to the construction of expression cassettes comprising nucleic acid sequences encoding for the highly glycosylated form of Erythropoietin and stable expression in the host cells. The invention further relates to the optimized method for purification of the erythropoiesis stimulating protein.

Abstract: The invention relates to extracts from Terminalia plant species that are capable of being used in methods for managing diseases such as cardiovascular disease, diabetes, degenerative neurological diseases, cancer, age related diseases like amyloidosis, acute pancreatitis, arthritis, atherosclerosis, cancer, heart diseases, inflammatory bowel disease, myocardial infarction, senile dementia, retinal degeneration and senile cataract; owing to the extracts antioxidation potential. The invention also relates to extracts from Terminalia plant species that are capable of being used in methods for managing various infectious diseases.

Abstract: The present invention relates to a cytoplasmic male sterility (CMS) transgenic plant prepared by RNA editing for expressing unedited nad 9 gene disenabling ATP production in the mitochondria of plants and a process for preparing the same. The said process comprises: cloning an un-edited nad 9 gene by digesting the PCR product obtained from mitochondrial DNA to obtain pNG3 cloning crop with un-edited nad 9 gene with the targeting sequence under ubiquitin promoter a NOS terminator to obtain pNG11 co-bombarding pNG11 constructs in a manner as herein described with hygromycin gene (pLAU6 hph construct) to generate plants containing un-edited nad 9 gene; analysing un-edited nad 9 (pNG11) construct with a control plant having edited nad 9 gene, pNG10 to determine the presence of nad 9 gene.

Abstract: The present invention relates to a process for biolistic transformation and regeneration of Pennisetum glaucum (Pearl millet) comprising: a) initiating embryogenic calli formation from the seeds of P glaucam in an MS media containing 5 mg/L of 2,4 D; b) incubating the said calli in dark for a predetermined period; c) sub-culturing the calli on an MS media containing 3 mg/L of 2.4 D; d) incubating said sub cultured calli under fight for a predetermined period; e) subjecting the embryogenic calli to biolistic bombardment with plasmid DNA containing pre-identified genes using a biolistic apparatus; f) allowing the proliferating calli to grow and differentiate into plantlets; g) analysing the expression of said pre-identified genes in the regenerated plantlets using known techniques.